SG Americas Securities LLC Buys 49,123 Shares of Collegium Pharmaceutical, Inc. $COLL

SG Americas Securities LLC raised its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 284.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 66,397 shares of the specialty pharmaceutical company’s stock after purchasing an additional 49,123 shares during the period. SG Americas Securities LLC owned 0.20% of Collegium Pharmaceutical worth $2,196,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. Evolve Private Wealth LLC lifted its position in Collegium Pharmaceutical by 5.9% in the first quarter. Evolve Private Wealth LLC now owns 23,520 shares of the specialty pharmaceutical company’s stock worth $778,000 after buying an additional 1,313 shares during the last quarter. Balboa Wealth Partners boosted its stake in Collegium Pharmaceutical by 57.7% during the first quarter. Balboa Wealth Partners now owns 7,115 shares of the specialty pharmaceutical company’s stock worth $235,000 after buying an additional 2,603 shares during the period. Hsbc Holdings PLC increased its position in Collegium Pharmaceutical by 78.0% during the fourth quarter. Hsbc Holdings PLC now owns 30,854 shares of the specialty pharmaceutical company’s stock valued at $1,429,000 after acquiring an additional 13,520 shares during the last quarter. Corient Private Wealth LLC increased its position in Collegium Pharmaceutical by 12.2% during the fourth quarter. Corient Private Wealth LLC now owns 7,866 shares of the specialty pharmaceutical company’s stock valued at $364,000 after acquiring an additional 858 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its stake in shares of Collegium Pharmaceutical by 205.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock valued at $29,000 after acquiring an additional 427 shares during the period.

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock opened at $35.87 on Thursday. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of 17.58 and a beta of 0.73. The company has a debt-to-equity ratio of 2.47, a current ratio of 1.71 and a quick ratio of 1.62. Collegium Pharmaceutical, Inc. has a 1 year low of $29.19 and a 1 year high of $50.79. The firm has a 50-day moving average of $34.20 and a two-hundred day moving average of $39.36.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.52 by $0.24. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The business had revenue of $193.52 million for the quarter, compared to analyst estimates of $184.47 million. During the same period last year, the company posted $1.49 earnings per share. The company’s quarterly revenue was up 8.9% compared to the same quarter last year. On average, research analysts forecast that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on COLL shares. Weiss Ratings cut shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, March 5th. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Zacks Research upgraded Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research report on Monday. Truist Financial raised Collegium Pharmaceutical to a “strong-buy” rating in a research note on Monday, June 15th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $56.00 price target (up from $54.00) on shares of Collegium Pharmaceutical in a report on Thursday, March 19th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Collegium Pharmaceutical currently has a consensus rating of “Buy” and a consensus price target of $57.50.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.